Dow Up0.76% Nasdaq Up0.69%

Amicus Therapeutics, Inc. (FOLD)

5.94 Up 0.13(2.24%) Oct 24, 3:59PM EDT
|After Hours : 5.94 0.00 (0.00%) Oct 24, 4:00PM EDT
ProfileGet Profile for:
Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury, NJ 08512
United States - Map
Phone: 609-662-2000
Fax: 609-662-2001

Index Membership:N/A
Full Time Employees:92

Business Summary 

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Amicus Therapeutics, Inc.

Corporate Governance 
Amicus Therapeutics, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. John F. Crowley , 47
Chairman and Chief Exec. Officer
Mr. William D. Baird III, 42
Chief Financial Officer and Sec.
Mr. Bradley L. Campbell , 38
Chief Operating Officer
Dr. Robert J. Desnick M.D., Ph.D.,
Ms. Daphne E. Quimi , 48
Principal Accounting Officer, VP of Fin. and Corp. Controller
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders